HRP20170702T1 - Inhibitori proteazoma za liječenje karcinoma - Google Patents
Inhibitori proteazoma za liječenje karcinoma Download PDFInfo
- Publication number
- HRP20170702T1 HRP20170702T1 HRP20170702TT HRP20170702T HRP20170702T1 HR P20170702 T1 HRP20170702 T1 HR P20170702T1 HR P20170702T T HRP20170702T T HR P20170702TT HR P20170702 T HRP20170702 T HR P20170702T HR P20170702 T1 HRP20170702 T1 HR P20170702T1
- Authority
- HR
- Croatia
- Prior art keywords
- bortezomib
- administered
- cancer
- multiple doses
- patient
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 9
- 201000011510 cancer Diseases 0.000 title claims 6
- 229940079156 Proteasome inhibitor Drugs 0.000 title 1
- 239000003207 proteasome inhibitor Substances 0.000 title 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 17
- 229960001467 bortezomib Drugs 0.000 claims 17
- 238000000034 method Methods 0.000 claims 8
- 238000011282 treatment Methods 0.000 claims 3
- 210000001072 colon Anatomy 0.000 claims 2
- 210000004100 adrenal gland Anatomy 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 238000011394 anticancer treatment Methods 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 210000000013 bile duct Anatomy 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000000621 bronchi Anatomy 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 238000001794 hormone therapy Methods 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000000244 kidney pelvis Anatomy 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000000116 mitigating effect Effects 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 210000003800 pharynx Anatomy 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (12)
1. Bortezomib za uporabu u postupku liječenja raka kod pacijenta, naznačen time da sadrži davanje navedenom pacijentu višestrukih doza navedenog bortezomiba, pri čemu se navedene višestruke doze daju barem četiri dana tjedno tijekom barem dva tjedna.
2. Bortezomib za uporabu u postupku prema zahtjevu 1, naznačen time da se navedeni bortezomib daje barem pet dana tjedno, ili pri čemu se navedeni bortezomib daje barem šest dana tjedno, ili gdje se navedeni bortezomib daje barem jednom dnevno.
3. Bortezomib za uporabu u postupku prema zahtjevu 1, naznačen time da se navedene višestruke doze daju barem jednom svakih 48 sati.
4. Bortezomib za uporabu u postupku prema zahtjevu 3, naznačen time da se navedene višestruke doze daju barem jednom svaka 24 sata.
5. Bortezomib za uporabu u postupku prema bilo kojem od zahtjeva 1-4, naznačen time da se navedene višestruke doze daju tijekom barem četiri tjedna.
6. Bortezomib za uporabu u postupku prema bilo kojem od zahtjeva 1-5, naznačen time da se navedeni bortezomib daje intravenozno, potkožno, parenteralno, intramuskularno, intradermalno ili transdermalno.
7. Bortezomib za uporabu prema bilo kojem od zahtjeva 1-6, naznačen time da je navedeni karcinom solidni tumor.
8. Bortezomib za uporabu u postupku prema zahtjevu 7, naznačen time da je navedeni solidni tumor izabran iz skupine koju čine tumori kože, pluća, bronhija, prostate, grudi, gušterače, adrenalne žlijezde, tankog crijeva, debelog crijeva, kolona, rektuma, tiroidne žlijezde, želuca, jetre, žučnih kanala, bubrega, bubrežne karlice, mokraćnog mjehura, maternice, cerviksa, jajnika, ezofagusa, mozga, glave i vrata, usne šupljine, ždrijela i grkljana.
9. Bortezomib za uporabu prema bilo kojem od zahtjeva 1-8, naznačen time da nadalje sadrži davanje navedenom pacijentu drugog tretmana protiv karcinoma.
10. Bortezomib za uporabu u postupku prema zahtjevu 9, naznačen time da je navedeni tretman protiv karcinoma odabran iz skupine koju čine antibiotska terapija, hormonska terapija, terapija zračenjem, kirurški zahvat, genska terapija, imunoterapija ili drugi tretmani za sprečavanje, liječenje ili ublažavanje karcinoma.
11. Bortezomib za uporabu u postupku prema zahtjevu 10, naznačen time da je navedena kemoterapija odabrana iz skupine koju čine anti-angiogeno sredstvo, anti-tumorsko sredstvo, citotoksično sredstvo i inhibitor stanične proliferacije.
12. Bortezomib za uporabu prema bilo kojem od zahtjeva 1-11, naznačen time da je navedeni karcinom refraktorni ili rekurentni.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24771409P | 2009-10-01 | 2009-10-01 | |
| PCT/EP2010/005994 WO2011038924A2 (en) | 2009-10-01 | 2010-10-01 | Treatment of disease with proteasome inhibitors |
| EP10807320.6A EP2519231B1 (en) | 2009-10-01 | 2010-10-01 | Proteasome inhibitors for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170702T1 true HRP20170702T1 (hr) | 2017-07-14 |
Family
ID=43629456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170702TT HRP20170702T1 (hr) | 2009-10-01 | 2017-05-11 | Inhibitori proteazoma za liječenje karcinoma |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20110189204A1 (hr) |
| EP (1) | EP2519231B1 (hr) |
| JP (1) | JP2013506626A (hr) |
| AU (2) | AU2010300259A1 (hr) |
| CA (1) | CA2776327A1 (hr) |
| CY (1) | CY1118925T1 (hr) |
| DK (1) | DK2519231T3 (hr) |
| ES (1) | ES2624644T3 (hr) |
| HR (1) | HRP20170702T1 (hr) |
| HU (1) | HUE032571T2 (hr) |
| LT (1) | LT2519231T (hr) |
| ME (1) | ME02725B (hr) |
| PL (1) | PL2519231T3 (hr) |
| PT (1) | PT2519231T (hr) |
| RS (1) | RS55931B1 (hr) |
| SI (1) | SI2519231T1 (hr) |
| WO (1) | WO2011038924A2 (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104039328B (zh) * | 2011-11-11 | 2018-10-09 | 米伦纽姆医药公司 | 对蛋白酶体抑制剂的反应的生物标记 |
| MX2017005530A (es) | 2014-10-30 | 2017-12-20 | Big Dna Ltd | Terapia de combinacion. |
| EP3365018A1 (en) * | 2015-10-20 | 2018-08-29 | The Cleveland Clinic Foundation | Stimulation of 11beta -hsd2 expression to improve hormonal therapy of steroid-dependent disease |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4499802A (en) * | 1982-09-29 | 1985-02-19 | Container Graphics Corporation | Rotary cutting die with scrap ejection |
| US4537773A (en) * | 1983-12-05 | 1985-08-27 | E. I. Du Pont De Nemours And Company | α-Aminoboronic acid derivatives |
| US4499082A (en) | 1983-12-05 | 1985-02-12 | E. I. Du Pont De Nemours And Company | α-Aminoboronic acid peptides |
| US5081110A (en) * | 1986-03-27 | 1992-01-14 | Sloan-Kettering Institute For Cancer Research | Method of killing sarcoma cells using fludarabine phosphate and ionizing radiation |
| US6083903A (en) * | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| CN1339970A (zh) * | 1999-02-10 | 2002-03-13 | 鹤尾隆 | 抗癌药物增强剂 |
| CA2435146C (en) * | 2001-01-25 | 2011-03-29 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Formulation of boronic acid compounds |
| CN101146533A (zh) | 2005-01-21 | 2008-03-19 | 阿斯泰克斯治疗有限公司 | 吡唑激酶抑制剂和其它抗肿瘤剂的组合 |
| AU2006207325B2 (en) | 2005-01-21 | 2012-08-16 | Astex Therapeutics Limited | Pharmaceutical compounds |
| US20060193844A1 (en) * | 2005-02-28 | 2006-08-31 | Proteolix, Inc. | Methods for enzyme inhibition |
| EP1876893B1 (en) | 2005-04-15 | 2012-04-11 | Geron Corporation | Cancer treatment by combined inhibition of proteasome and telomerase activities |
| TW200836749A (en) | 2007-01-09 | 2008-09-16 | Vioquest Pharmaceuticals Inc | Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof |
| KR101544498B1 (ko) * | 2007-08-24 | 2015-08-17 | 스티칭 허트 네덜란드 칸커 인스티튜트 | 종양성 질환의 치료를 위한 조성물 |
-
2010
- 2010-10-01 ME MEP-2017-106A patent/ME02725B/me unknown
- 2010-10-01 US US12/896,289 patent/US20110189204A1/en not_active Abandoned
- 2010-10-01 WO PCT/EP2010/005994 patent/WO2011038924A2/en active Application Filing
- 2010-10-01 SI SI201031448A patent/SI2519231T1/sl unknown
- 2010-10-01 JP JP2012531285A patent/JP2013506626A/ja active Pending
- 2010-10-01 PT PT108073206T patent/PT2519231T/pt unknown
- 2010-10-01 HU HUE10807320A patent/HUE032571T2/en unknown
- 2010-10-01 ES ES10807320.6T patent/ES2624644T3/es active Active
- 2010-10-01 AU AU2010300259A patent/AU2010300259A1/en not_active Abandoned
- 2010-10-01 RS RS20170474A patent/RS55931B1/sr unknown
- 2010-10-01 CA CA2776327A patent/CA2776327A1/en not_active Abandoned
- 2010-10-01 DK DK10807320.6T patent/DK2519231T3/en active
- 2010-10-01 PL PL10807320T patent/PL2519231T3/pl unknown
- 2010-10-01 LT LTEP10807320.6T patent/LT2519231T/lt unknown
- 2010-10-01 EP EP10807320.6A patent/EP2519231B1/en not_active Revoked
-
2016
- 2016-12-22 AU AU2016277700A patent/AU2016277700A1/en not_active Abandoned
-
2017
- 2017-05-11 HR HRP20170702TT patent/HRP20170702T1/hr unknown
- 2017-06-01 CY CY20171100580T patent/CY1118925T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011038924A2 (en) | 2011-04-07 |
| WO2011038924A3 (en) | 2011-05-26 |
| ES2624644T3 (es) | 2017-07-17 |
| CY1118925T1 (el) | 2018-01-10 |
| EP2519231B1 (en) | 2017-03-15 |
| JP2013506626A (ja) | 2013-02-28 |
| CA2776327A1 (en) | 2011-04-07 |
| DK2519231T3 (en) | 2017-06-26 |
| PL2519231T3 (pl) | 2017-09-29 |
| WO2011038924A9 (en) | 2011-07-14 |
| LT2519231T (lt) | 2017-05-10 |
| RS55931B1 (sr) | 2017-09-29 |
| EP2519231A2 (en) | 2012-11-07 |
| AU2016277700A1 (en) | 2017-02-02 |
| PT2519231T (pt) | 2017-05-25 |
| US20110189204A1 (en) | 2011-08-04 |
| AU2010300259A1 (en) | 2012-04-26 |
| SI2519231T1 (sl) | 2017-07-31 |
| HUE032571T2 (en) | 2017-09-28 |
| ME02725B (me) | 2017-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200991T1 (hr) | Modulator androgenog receptora u kombinaciji s abirateron acetatom i prednizonom za liječenje karcinoma prostate | |
| Giancola et al. | Osteonecrosis of the jaw related to everolimus and bisphosphonate: a unique case report? | |
| JP2015520753A5 (hr) | ||
| HRP20170702T1 (hr) | Inhibitori proteazoma za liječenje karcinoma | |
| EA201200560A1 (ru) | Специфическая терапия, использующая интегриновые лиганды для лечения рака | |
| EA201490911A1 (ru) | Способы лечения злокачественных опухолей с использованием пероральных составов аналогов цитидина | |
| JP2011103891A5 (hr) | ||
| HK1071310A1 (en) | Combination therapy for the treatment of cancer | |
| MX2009007597A (es) | Terapia especifica y medicamento que utilizan ligandos de integrina para tratar el cancer. | |
| NZ596739A (en) | Methods of treating proliferative diseases | |
| WO2016133903A3 (en) | Combination therapy for cancer treatment | |
| RU2019142694A (ru) | Композиции и способы, которые можно использовать для лечения пролиферативных заболеваний | |
| JP2017214420A (ja) | 樹状細胞癌ワクチンのための小分子エンハンサー | |
| MY169330A (en) | Method for inhibition of deubiquitinating activity | |
| RU2010151787A (ru) | Антиопластические комбинации, содержащие нкi-272 и винорелбин | |
| EP4218760A3 (en) | Treatment regimen utilizing neratinib for breast cancer | |
| RU2015152785A (ru) | Лечение злокачественной опухоли налтрексоном | |
| MX2019002066A (es) | Regimen de dosificacion para el tratamiento de tumores solidos. | |
| MX2022000430A (es) | Administracion de agonista de sting e inhibidores de puntos de control. | |
| MX2022006566A (es) | Tratamientos conjuntos para tratamiento de cancer de mama. | |
| IL259512B2 (en) | Combination for effective treatment of metastatic cancer in patients | |
| MX2021007565A (es) | Composiciones y metodos para la terapia contra el cancer. | |
| JP2018511642A5 (hr) | ||
| JP2013506626A5 (hr) | ||
| EA200601471A1 (ru) | Ингибиторы клеточной пролиферации клеток (варианты), фармацевтическая композиция на их основе, способ уничтожения раковых клеток (варианты) и способ лечения и профилактики злокачественных состояний (варианты) |